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Abstract
Background: The study aimed to investigate the utility of dynamic contrast enhanced MRI (DCE-MRI) in the
differentiation of malignant, borderline, and benign complex ovarian tumors.
Methods: DCE-MRI data of 102 consecutive complex ovarian tumors (benign 15, borderline 16, and malignant
71), confirmed by surgery and histopathology, were analyzed retrospectively. The patterns (I, II, and III) of
time-signal intensity curve (TIC) and three semi-quantitative parameters, including enhancement amplitude (EA),
maximal slope (MS), and time of half rising (THR), were evaluated and compared among benign, borderline, and
malignant ovarian tumors. The types of TIC were compared by Pearson Chi-square χ2 between malignant and
benign, borderline tumors. The mean values of EA, MS, and THR were compared using one-way ANOVA or
nonparametric Kruskal-Wallis test.
Results: Fifty-nine of 71 (83%) malignant tumors showed a type-III TIC; 9 of 16 (56%) borderline tumors showed a
type-II TIC, and 10 of 15 (67%) benign tumors showed a type-II TIC, with a statistically significant difference between
malignant and benign tumors (P < 0.001) and between malignant and borderline tumors (P < 0.001). MS was
significantly higher in malignant tumors than in benign tumors and in borderline than in benign tumors (P < 0.001,
P = 0.013, respectively). THR was significantly lower in malignant tumors than in benign tumors and in borderline than
in benign tumors (P < 0.001, P = 0.007, respectively). There was no statistically significant difference between malignant
and borderline tumors in MS and THR (P = 0.19, 0.153) or among malignant, borderline, and benign tumors in
EA (all P > 0.05).
Conclusions: DCE-MRI is helpful for characterizing complex ovarian tumors; however, semi-quantitative
parameters perform poorly when distinguishing malignant from borderline tumors.
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Background
Ovarian tumors represent a remarkably heterogeneous
group of benign, borderline, and malignant neoplasms
that usually result in significant diagnostic challenges
to radiologists, surgeons, and pathologists [1–3]. The
preoperative qualitative diagnosis and accurate
characterization of ovarian tumors are the key steps
for an optimal clinical treatment strategy, which is
also helpful for improving patient prognosis [2–4].
During the past decade, some have already voiced
strong concerns about the individualized treatment of
ovarian tumors, especially in borderline and some
subtypes of early-stage malignant tumors, because a
conservative, fertility-sparing surgery can be considered
for patients who wish it [5–8]. Therefore, considerable
new insight has been achieved in understanding those
tumors.
Ovarian tumors are mainly diagnosed by preoperative
imaging. Ultrasound is generally used as a first-choice
examination for screening ovarian lesions; however, it is
not always helpful for the definitive diagnosis of some
indeterminate ovarian tumors. Magnetic resonance
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imaging (MRI) has been proven to provide more ana-
tomical information of ovarian masses and adjacent
structures through its high spatial resolution and soft-
tissue contrast and is helpful for differentiating diagnosis
[2, 3]. However, although some morphological character-
istics have been described, there are still some overlap-
ping features on conventional MRI among ovarian
tumors. As an advanced technique, dynamic contrast en-
hanced MRI (DCE-MRI) could be used not only to assess
the microcirculatory perfusion and vascular permeability
in ovarian tumors noninvasively, but provide a more
comprehensive discrimination of ovarian tumors ac-
cording to the time-intensity curves (TIC) and some
semi-quantitative parameters [9, 10].
Previous studies have shown the advantages and the
availability of semi-quantitative DCE-MRI in characteriz-
ing ovarian tumors [9–14]. The latest study including all
histopathological types of ovarian masses showed that
semi-quantitative DCE-MRI could discriminate malig-
nant from borderline and benign tumors [14]. The stud-
ies that include only epithelial ovarian tumors showed
similar results [9, 10]. However, standardization of
scanning techniques and data processing is still
needed to validate the semi-quantitative DCE-MRI in
the characterization of complex ovarian masses.
Methods
Patient population
The institutional review board approved this retrospect-
ive study, and informed consent was waived. From Feb-
ruary 2011 to October 2014, a total of 131 consecutive
patients who were suspected of having complex ovarian
tumors underwent DCE-MRI scanning. We excluded 15
patients who had not undergone surgery, 5 patients who
received prior chemotherapy before MRI scanning, 4 pa-
tients with a poor imaging quality, and 5 patients with-
out obvious solid components. Finally, 102 patients with
15 benign, 16 borderline, and 71 malignant ovarian tu-
mors were included. All tumors were proven by surgery
and histopathology within 2 weeks after the MR scan.
The histopathological types of ovarian tumors are listed
in Table 1. Patients’ ages ranged from 24 to 88 years
(mean, 57 ± 15 years; median age, 57 years) in benign tu-
mors, 16 to 58 years (mean, 37 ± 13 years; median age,
37 years) in borderline tumors, and 15 to 83 years
(mean, 54 ± 12 years; median, 56 years) in malignant tu-
mors, with a statistically significant difference between
borderline and benign (P = 0.001) and between border-
line and malignant tumors (P < 0.001).
MRI scanning
MRI was performed using a 1.5-T scanner (Avanto or
Espree; Siemens, Erlangen, Germany) with a phased-
array abdominal coil. The patients lay in a supine
position and breathed freely during acquisition. The pa-
rameters of conventional sequences are listed in Table 2.
After completing four phases of scans, the axial DCE
flashes 2D, T1-weighted imaging (T1WI) with fat satur-
ation focusing on the solid components (solid portions,
vegetations, thickened septa) was performed after the
intravenous administration of 0.2 mmol/kg Gadopente-
tate dimeglumine (Gd-DTPA, Magnevist; Bayer Scher-
ing, Berlin, Germany) at a rate of 3.0 ml/s, followed by
injection of 20 ml of normal saline to flush the tube.
The scanning parameters were as follows: TR/TE = 5.6/
2.38 ms, slice thickness 4 mm; gap 1.0 mm; matrix
256 × 256; field of view 280–340 mm, flip angle 10°,
NEX = 1. A total of 30 phases of scans were obtained se-
quentially at 7-s intervals for 3 min 20 s. Every phase
consists of 20 images.
Semi-quantitative DCE-MRI analysis
MR images were reviewed independently by two radiolo-
gists (H.M.L. and J.W.Q., with 7 and 31 years of experi-
ence in gynecological imaging, respectively) who were
blinded to the original reports (radiology, clinic, and
histopathology). Any discrepancies were resolved by
consensus. The MR features (tumor maximal diameters,
bilaterality, shape, boundary, mass configuration, signal
intensity [SI] on T2-weighted imaging (T2WI), ascites/
pelvic fluid, and peritoneal implants/lymph nodes) were
assessed. The time-signal intensity curve (TIC) was
Table 1 Histopathologic type in 102 ovarian tumors
Groups Histopathologic types Number
Benign (n = 15) Fibrothecoma/thecoma 11
Fibroma 3
Stromal tumor with minor sex-cord
elements
1




Malignant (n = 71) High-grade serous adenocarcinoma 31






Sertoli-Leydig cell tumor 1
Malignant germ-cell tumor 4
Secondary tumor 9
Neuroendocrine carcinoma 1
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generated using the Mean Curve software package
(Siemens). The semi-quantitative DCE-MRI parameters,
including enhancement amplitude (EA), maximal slope
(MS), and time of half rising (THR), were calculated.
A round region of interest (ROI) of at least 1 cm2
was placed at targeted areas referring to T2WI and
contrast-enhanced images and avoiding areas such as
hemorrhage, necrosis, and major vascular structures.
TIC was classified into three types referring to study of
Thomassin-Naggara et al. Type I curve showed a gradual
slow rising; type III had a rapid rising followed by a plat-
eau or slow-out curve. Type II curve had a moderate ris-
ing (lower than the type III and higher than the type I).
The EA is the maximal value on the y-axis, MS is the
maximal ratio of signal intensity increasing in one scan-
ning period, and THR is the time from the injection of
Gd-DTPA to reach half of the EA. In patients with bilat-
eral masses (25 patients with ovarian malignant tumors,
6 patients with serous borderline ovarian tumors), only
the most complex mass was evaluated to reduce intra-
individual influence.
Statistical analysis
Statistical analysis was performed with SPSS 23.0 for
Windows (SPSS Inc., Chicago, IL, USA). The differences
in laterality, shape, boundary, mass configuration, SI on
T2WI, ascites/pelvic fluid, peritoneal implants/lymph
nodes, and TIC types among benign, borderline, and
malignant tumors were compared using the Pearson
Chi-square test or Fisher’s exact test. The differences in
the age, diameters, and the parameters of EA, MS, and
THR among the three groups of tumors were compared
using one-way analysis of variance (ANOVA) or the
nonparametric Kruskal-Wallis test. Receiver operating
characteristic (ROC) curves were used to determine the
cutoff values of semi-quantitative DCE-MRI parameters
(MS and THR) for distinguishing between benign and
malignant (borderline and malignant) tumors. A p-value
less than 0.05 was considered statistically significant, and
when the two-two comparisons were done by Pearson




The MRI morphological features are summarized in
Table 3. A significant difference was found in the bilateral-
ity (P = 0.021, 0.006), shape (P = 0.001, 0.001), mass con-
figuration (P = 0.009, 0.001), and peritoneal implants/
lymph nodes (P = 0.006, 0.003) among the three groups
and between benign and malignant tumours, respectively.
Table 2 Parameters for MRI imaging sequences
T1WI T2WI Contrast-enhanced T1WI
Parameters Axial Axial Sagittal Coronal Sagittal Axial
Sequence 2D SE 2D TSE 2D FSE 2D FSE 2D FSE 2D SPGR
Repetition time (msec) 761 8000 4490 4420 724 4.89
Echo time (msec) 10 83 83 83 10 2.38
Field of view (mm) 340–420 340–420 260–340 380–420 260–340 340–420
Matrix 480 × 640 256 × 256 256 × 256 320 × 320 256 × 256 256 × 256
Flip angle (degree) 150 150 144 144 150 10
Slice thickness/gap (mm) 5/1.0 5/2.0 5/1.5 5/1.5 5/1.5 5/1.5
Averages (NEX) 1 1 1 1 1 2
Acquisition time (sec) 100 100 162 96 120 42








Maximal diameters (cm) 8.8 ± 3.9 10.1 ± 5.0 9.9 ± 4.0 0.531a
Bilateral 0 (0) 6 (38%) 25 (35%) 0.021b
Shape
Round/oval 13 (87%) 11 (69%) 28 (39%) 0.001b
Lobulated/irregular 2 (13%) 5 (31%) 43 (61%)
Boundary
Clear 15 (100%) 13 (81%) 38 (54%) 0.001b
Obscure 0 (0) 3 (19%) 33 (46%)
Mass configuration
Mainly cystic 0 (0) 9 (56%) 25 (35%) 0.009b
Mixed cystic and solid 2 (13%) 1 (6%) 13 (18%)
Mainly solid 13 (87%) 6 (38%) 33 (47%)
SI on T2-weighted imaging
Hyperintensity 10 (67%) 13 (81%) 59 (83%) 0.345b
Iso-/hypointensity 5 (33%) 3 (19%) 12 (17%)
Ascites/pelvic fluid 10 (67%) 8 (50%) 42 (59%) 0.638b
Peritoneal implants/lymph
nodes
0 (0) 3 (19%) 28 (39%) 0.006b
Notes: aANOVA; bPearson Chi-square χ2 test; SI signal intensity
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A significant difference was also found in mass configur-
ation between benign and borderline tumors (P = 0.003).
However, there was no statistically significant difference
between borderline and malignant tumors.
Type of TIC
There were 59 (83%) type III, 12 (17%) type II, and no type
I of TIC in malignant ovarian tumors; 4 (25%) type III, 9
(56%) type II, and 3 (19%) type I of TIC in borderline tu-
mors; and 5 (33%) type I, 10 (67%) type II, and no type III
of TIC in benign tumors, with a statistically significant dif-
ference between malignant and benign tumors (P < 0.001)
and between malignant and borderline tumors (P < 0.001)
(Figs. 1, 2 and 3). There was no statistically significant dif-
ference between borderline and benign tumors (P = 0.104).
If type III TIC indicated a malignant tumor, type II and I
TIC represented a benign or borderline tumor; it would
generate a sensitivity of 83% (59/71), a specificity of 100%
(15/15), and an accuracy of 86% (74/86) between malig-
nant and benign tumors and a sensitivity, specificity, and
accuracy of 83% (59/71), 75% (12/16), and 82% (71/87) be-
tween malignant and borderline tumors, respectively.
Semi-quantitative DCE-MRI
The mean values of EA, MS, and THR in the three
groups of tumors are shown in Table 4. In benign,
borderline, and malignant tumors, the mean value of
EA was 220.2 ± 90.5, 269.3 ± 70.9, and 267.4 ± 86.2, re-
spectively, without significant difference in overall
and in two-two comparisons (all P > 0.05). The mean
value of MS was higher in malignant than in border-
line tumors and higher in borderline tumors than in
benign tumors, whereas the mean value of THR in
malignant tumors was lower than in borderline tu-
mors and significantly lower in borderline tumors
than in benign tumors. There was a significant differ-
ence overall (P = 0.001, < 0.001, respectively) between
benign and malignant (P < 0,001, 0.001, respectively),
borderline tumors (P = 0.013, 0.007, respectively). How-
ever, no significant difference was observed between
borderline and malignant tumors (P = 0.19, 0.53,
respectively).
Diagnostic performance of semi-quantitative DCE-MRI
parameters
Receiver operating characteristic (ROC) analysis was
performed for the two statistically significant parameters
of MS and THR to evaluate diagnostic ability in distin-
guishing malignant from benign tumors and borderline
from benign tumors. The area under the curve (AUC),
the cutoff value, and the diagnostic performance are
listed in Table 5.
Fig. 1 A 60-year-old woman with ovarian high-grade serous adenocarcinoma. Axial T2WI with fat suppression (a) demonstrated bilateral ovarian
masses (white arrow) with peritoneal seeds (black arrowheads) and a large volume of ascites (asterisk). The mural nodule (red ROI) showed obvious
contrast enhancement compared with the myometrium (yellow ROI) on contrast-enhanced T1WI with fat suppression (b). The mural nodule
showed a curve of type III (a rapid rising and plateau pattern) (c)
Fig. 2 A 26-year-old woman with ovarian seromucinous borderline tumor. Axial T2WI with fat suppression (a) demonstrated a left-side ovarian
mass with mural nodule (white arrow). The mural nodule (red ROI) showed a moderate contrast enhancement compared with the myometrium
(yellow ROI) on contrast-enhanced T1WI with fat suppression (b). The mural nodule showed a curve of type II (a moderate rising pattern) (c)
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Discussion
Angiogenesis is the process of formation of new blood
vessels from preexisting blood vessels, which is the funda-
ment of the growth, progression, invasion, and metastasis
of nearly all tumors [15]. The process of angiogenesis is
regulated by a variety of tumor angiogenic factors such as
vascular endothelial growth factor (VEGF) and its recep-
tor [16]. Malignant tumors were generally hypervascular
with immature and fragile tumor vessels, which could in-
crease the vascular permeability, whereas hypovascularity
was characteristic of benign tumors with integrally mor-
phological and functional vessels. DCE-MRI could make
qualitative, semi-quantitative, and quantitative evaluation
of blood perfusion in ovarian tumors based on the differ-
ent enhancement pattern [17]. The semi-quantitative
parameters were obtained by way of analyzing the patterns
of TIC and were simple and feasible, whereas the quanti-
tative parameters were derived with a complicated phar-
macokinetic model.
Analyzing the type of TIC was already widely used in
some clinical settings, particularly in differentiating malig-
nant from benign tumors in breast and prostate carcinoma
[18–20]. However, comprehensive use in ovarian tumors
was nevertheless rare [21]. Our findings demonstrated that
the TIC type was accurate for distinguishing malignant
from benign ovarian tumors; however, it had a substantial
overlap between borderline and malignant tumors and
showed no significant difference between benign and
borderline tumors. As we know, the degree of signal
enhancement depends on physiological and physical fac-
tors, including tissue perfusion, arterial input function
(AIF), capillary surface area, permeability, and extracellular
extravascular space [22]. Angiogenesis may differ among
different tumor types. Some malignant tumors, such as
mucinous adenocarcinoma, may appear to be hypovascu-
lar, whereas some benign tumors such as thecoma or scler-
osing stromal tumor, show abundant vascularity [2, 11]. In
addition, the TIC type of tumor depends on visual and sub-
jective assessment of contrast enhancement [20]. There-
fore, TIC type alone could not definitely discriminate
borderline from benign and malignant ovarian tumors. A
combination of the semi-quantitative parameter analysis of
TIC is needed to improve the diagnostic accuracy.
The value of EA represented the amount of contrast
agent in the tumor vessels. In theory, the EA was higher
in malignant than in borderline tumors and higher in
borderline tumors than in benign tumors, which was
confirmed by several studies [9, 10, 13, 14]. However,
our study showed that the mean EA of malignant tu-
mors was slightly lower than in borderline tumors and
higher than in benign tumors (267.4 ± 86.2 vs. 269.3 ±
70.0 and 220.2 ± 90.5) (P > 0.05), which was not in ac-
cordance with previous studies [9, 10, 13, 14]. Therefore,
further work needs to be done to verify our present find-
ings. The MS and THR represented the rate of contrast
agent in and out of the tumor vessel. Our preliminary
findings showed the MS and THR were helpful for dis-
tinguishing malignant from benign tumors and border-
line from benign tumors. The results of the ROC
analysis were also promising, and THR was a better indi-
cator than MS in distinguishing malignant from benign
tumors (sensitivity, 94%; specificity, 80%; accuracy, 92%)
and borderline from benign tumors (sensitivity, 88%;
specificity, 80%; accuracy, 84%). These differences in
THR and MS among the three groups of tumors were
mainly due to a number of variables in angiogenesis.
Malignant tumors have aberrant vascular structure, al-
tered endothelial-cell–pericyte interactions, increased
permeability, and delayed maturation of vessels, which
Fig. 3 A 42-year-old woman with ovarian fibrothecoma. Axial T2WI with fat suppression (a) demonstrated a left-side ovarian solid mass (white
arrow). The mass (red ROI) showed a mild contrast enhancement compared with the myometrium (yellow ROI) on contrast-enhanced T1WI with
fat suppression (b). The mass showed a curve of type I (a gradual slow-rising pattern) (c)
Table 4 Comparison of semi-quantitative DCE-MRI parameters
for three groups
Tumor type Semi-quantitative DCE-MRI parameters
EAa MSb THRa
Benign 220.2 ± 90.5 6.1 ± 4.7cd 55.5 ± 15.4cd
Borderline 269.3 ± 70.9 8.5 ± 3.4 37.3 ± 15
Malignant 267.4 ± 86.2 11.0 ± 6.3 32.4 ± 8.5
Note: aANOVA; bKruskal-Wallis nonparametric test. P <0.05: Benign vs.
Borderline (c); Benign vs. Malignant (d); EA enhancement amplitude, MS
maximal slope, THR time of half rising
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could make the contrast agent penetrate the interstitial
space more quickly [23], whereas benign tumors have
fewer and relatively mature vessels, which show no obvi-
ous change in permeability and microcirculation.
Borderline ovarian tumors represented a heterogeneous
group of masses with relatively good prognosis and a
younger age. A conservative, fertility-sparing surgery
could be considered for patients who wish to preserve fer-
tility [5, 6]. Preoperative imaging, then, can significantly
contribute by accurately identifying borderline ovarian tu-
mors, although Medeiros’s studies and our present study
showed the difficulty of conventional MRI in differentiat-
ing between borderline and malignant tumors [24]. TIC
type showed a significant difference between malignant
and borderline tumors, with a sensitivity, specificity, and
accuracy of 83%, 75%, and 82%, respectively. Unfortu-
nately, the three semi-quantitative parameters performed
poorly and did not contribute to a differentiation of these
two groups, which was inconsistent with some previous
studies [9, 10, 13, 14]. The results were probably due to
the diversity of samples and histopathological complexity
of the tumors. For instance, mucinous borderline tumors
have a lower EA and MS values and a higher THR value
than other types of borderline tumors (195.9 ± 58.9
vs. 293.8 ± 57.3; 7.1 ± 5.9 vs. 8.9 ± 2.3; 42.3 ± 28.1 vs.
35.7 ± 8.8), respectively (P = 0.011, 0.586, 0.674). Only
4 (25%) mucinous borderline tumors were included in
our study, versus 46%–50% of tumors in the studies
of Thomassin-Naggara and Mansour [9, 14].
Several limitations should be addressed in our study.
First, patient selection bias existed because of the retro-
spective nature. Second, a limited number of patients
with benign and borderline tumors were included; in
particular, some mucinous borderline tumors with few
solid components were excluded. Third, the DCE-MRI
scans were obtained sequentially for a total of 3 min
20 s in our study; a longer dynamic acquisition time
should be used to yield more accurate parameters.
Conclusions
Our preliminary findings suggest that semi-quantitative
DCE-MRI is useful for distinguishing malignant from
benign tumors and borderline from benign tumors, but
not for differentiating malignant from borderline tu-
mors, although there is a different TIC type. Therefore,
further studies, combining other imaging techniques
such as quantitative DCE-MRI, magnetic resonance
spectroscopy, and diffusion-weighted imaging, are
warranted.
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